Visus presbyopia drop gets FDA IND OK

Video

A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application

Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Billy R. Hammond details the study, which explored how HEV-light filtering, specifically in the 380-440 nanometer range, impacts visual comfort for patients with presbyopia.
Kurt Moody, OD, FAAO, describes how to fit multifocal contact lenses in a way that patients love
Jacob R. Lang, OD, FAAO
© 2025 MJH Life Sciences

All rights reserved.